Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co Buyback Yield % Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
Buyback Yield %
0.00
0.00
0.00
Middle East Pharmaceutical Industries Co Quarterly Data
SAU:4016 vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co Buyback Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co (SAU:4016) has a Buyback Yield % of 0.00 as of Jul. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Middle East Pharmaceutical Industries Co and its competitors. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Middle East Pharmaceutical Industries Co's Buyback Yield % too high?
Middle East Pharmaceutical Industries Co's current Buyback Yield % is 0.00. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #999999 out of 290 companies for Buyback Yield %. This places Middle East Pharmaceutical Industries Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Middle East Pharmaceutical Industries Co and its competitors. Middle East Pharmaceutical Industries Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current Buyback Yield % is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co Business Description
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score
Get the complete analysis for SAU:4016
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
